Fig. 1: Expression and characterization of in vivo-launched SARS-CoV-2 DMAb constructs.

WT DMAb expression (100 μg dose) following a single plasmid (n = 5 (2196_WT and 2130_WT) or 4 (2381_WT) independent biological replicates) or b dual plasmid constructs (n = 5) was measured in the sera of 6–8-week-old female BALB/c mice. Serum DMAb titers for individual mice over time are shown. Lines indicate the group geometric means (GM). c Neutralization of pseudotyped SARS-CoV-2 (USA-WA1/2020) by serum pools (from panel b). Neutralization curves for each pool are shown (best fit lines and individual data points derived from technical replicates); ID50 and calculated IC50 values are displayed. d DMAb levels in the lung bronchoalveolar lavage (BAL) of 6–8-week-old female BALB/c mice at D14 post-plasmid delivery (100 μg dose; n = 13 (2130_WT) or 14 (2196_WT) independent biological replicates). Titers for individual mice are shown with group GM (±geometric standard deviation (GSD)) indicated. e-i Expression and characterization of WT and TM DMAb constructs in 6–8-week-old female K−18 mice (100 μg dose; n = 5). e Titers for individual animals (independent biological replicates) over time are shown. Lines indicate the group geometric means (GM)). f Neutralizing activity of pooled sera against authentic SARS-CoV-2 virus (USA-WA1/2020). Graph depicts ID50 and calculated IC50 for each pool. LOD = limit of detection. g Reactivity of pooled sera against indicated epitope-specific mutant RBDs. Binding curves (OD450) of each pool (average of technical replicates) are shown. h-i ACE2 receptor-blocking activity of individual sera samples from e (n = 5 biological replicates) was determined; h proportion (%) of ACE-2 blocking relative to control wells (group mean ± SD) and i calculated blocking DMAb titer (GM (±GSD). Data representative of >2 independent experiments with similar results. Source data are provided as a Source Data file.